公开(公告)号：US07888067B2

公开(公告)日：2011-02-15

申请号：US12624226

申请日：2009-11-23

Applicant: Shu-Wha Lin ,  Chia-Ni Lin ,  Hua-Lin Wu ,  Guey-Yueh Shi

Inventor： Shu-Wha Lin ,  Chia-Ni Lin ,  Hua-Lin Wu ,  Guey-Yueh Shi

IPC: C12P21/06

CPC classification number: C12N9/644 ,  A61K38/00 ,  C12Y304/21022

Abstract: The present invention aims at converting factor IX into a molecule with enhanced activity which provides an alternative for replacement therapy and gene therapy for hemophilia B. Using recombinant techniques, factor IX with replacement at positions 86, 277, and 338 exhibits better clotting activity than recombinant wild type factor IX.

Abstract translation: 本发明旨在将因子IX转化为具有增强的活性的分子，其为血友病B的替代疗法和基因治疗提供替代方案。使用重组技术，在位置86,277和338处置换的因子IX表现出比重组更好的凝血活性 野生型因子IX。

公开(公告)号：US20100303800A1

公开(公告)日：2010-12-02

申请号：US12856556

申请日：2010-08-13

Applicant: Hua-Lin WU ,  Guey-Yueh Shi

Inventor： Hua-Lin WU ,  Guey-Yueh Shi

IPC: A61K38/48 ,  A61K38/00 ,  A61P9/10

CPC classification number: A61K48/00 ,  A61K38/366

Abstract: A method for treating ischemia that would benefit from angiogenesis is disclosed. The method comprises administering to a subject in need thereof a composition comprising: a) a fragment of human thrombomodulin in a therapeutically effective amount; and b) a pharmaceutically acceptable carrier; wherein the fragment comprises the amino acids Ala242 to Ser515 of SEQ ID NO: 2.

Abstract translation: 公开了一种治疗从血管发生中受益的缺血的方法。 该方法包括向有需要的受试者施用组合物，其包含：a）治疗有效量的人血栓调节素片段; 和b）药学上可接受的载体; 其中所述片段包含SEQ ID NO：2的氨基酸Ala242至Ser515。

公开(公告)号：US07700734B2

公开(公告)日：2010-04-20

申请号：US11935779

申请日：2007-11-06

Applicant: Shu-Wha Lin ,  Chia-Ni Lin ,  Hua-Lin Wu ,  Guey-Yueh Shi

Inventor： Shu-Wha Lin ,  Chia-Ni Lin ,  Hua-Lin Wu ,  Guey-Yueh Shi

IPC: A61K35/14

CPC classification number: C12N9/644 ,  A61K38/00 ,  C12Y304/21022

Abstract: The present invention aims at converting factor IX into a molecule with enhanced activity which provides an alternative for replacement therapy and gene therapy for hemophilia B. Using recombinant techniques, factor IX having substitution of amino acid residue of SEQ ID NO: 7 at amino acid position selected from the group consisting of 86, 277, and 338 (exclude the circumstance of a single substitution at amino acid position 338) exhibits better clotting activity than recombinant wild type factor IX.

Abstract translation: 本发明旨在将因子IX转化为具有增强活性的分子，其为血友病B的替代疗法和基因治疗提供替代方案。使用重组技术，在氨基酸位置取代SEQ ID NO：7的氨基酸残基的因子IX 选自86,277和338（排除在氨基酸位置338处的单个取代的情况）显示出比重组野生型因子IX更好的凝血活性。

公开(公告)号：US20080167219A1

公开(公告)日：2008-07-10

申请号：US11935779

申请日：2007-11-06

Applicant: Shu-Wha Lin ,  Chia-Ni Lin ,  Hua-Lin Wu ,  Guey-Yueh Shi

Inventor： Shu-Wha Lin ,  Chia-Ni Lin ,  Hua-Lin Wu ,  Guey-Yueh Shi

IPC: A61K38/36 ,  C07K14/745 ,  A61K48/00 ,  C07H21/00

CPC classification number: C12N9/644 ,  A61K38/00 ,  C12Y304/21022

Abstract: The present invention aims at converting factor IX into a molecule with enhanced activity which provides an alternative for replacement therapy and gene therapy for hemophilia B. Using recombinant techniques, factor IX with replacement at positions 86, 277, and 338 exhibits better clotting activity than recombinant wild type factor IX.

Abstract translation: 本发明旨在将因子IX转化为具有增强的活性的分子，其为血友病B的替代疗法和基因治疗提供替代方案。使用重组技术，在位置86,277和338处置换的因子IX表现出比重组更好的凝血活性 野生型因子IX。

公开(公告)号：US07087721B2

公开(公告)日：2006-08-08

申请号：US10938183

申请日：2004-09-10

Applicant: Hua-Lin Wu ,  Guey-Yueh Shi ,  Huey-Chun Huang

Inventor： Hua-Lin Wu ,  Guey-Yueh Shi ,  Huey-Chun Huang

IPC: A61K35/14 ,  C07K14/00

CPC classification number: C07K16/36 ,  A61K31/7004 ,  A61K31/737 ,  A61K38/36 ,  A61K45/06 ,  C07K14/7455 ,  C07K2317/76 ,  G01N33/574 ,  A61K2300/00

Abstract: The present invention relates to compositions, kits and treating methods for the alteration cell-cell adhesion, transport, or permeation properties of tissues. The present invention also relates to the application of drug(s) or peptide(s), compound or gene delivery, DNA or RNA(i), cosmetic or therapeutic use of the compositions and kits.

Abstract translation: 本发明涉及用于改变组织的细胞粘附，转运或渗透性质的组合物，试剂盒和治疗方法。 本发明还涉及药物或肽，化合物或基因递送，DNA或RNA（i），组合物和试剂盒的美容或治疗用途的应用。

公开(公告)号：US20060148706A1

公开(公告)日：2006-07-06

申请号：US11361560

申请日：2006-02-24

Applicant: Hua-Lin Wu ,  Guey-Yueh Shi ,  Chuan-Chi Chiang ,  Hui-Pin Su

Inventor： Hua-Lin Wu ,  Guey-Yueh Shi ,  Chuan-Chi Chiang ,  Hui-Pin Su

IPC: A61K38/18

CPC classification number: A61K48/00 ,  A61K38/366

Abstract: The invention relates to a method for treatment of wound healing, comprising administering to a patient in need of such treatment with an effective amount of a polypeptide comprising amino acid sequence or a conservative variant thereof having EGF-like domain of thrombomodulin. The invention also relates to a composition for the use of accelerating wound healing, comprising a polypeptide comprising amino acid sequence or a conservative variant thereof having EGF-like domain of thrombomodulin.

Abstract translation: 本发明涉及一种治疗伤口愈合的方法，其包括向需要这种治疗的患者施用有效量的包含氨基酸序列的多肽或其具有血栓调节蛋白EGF样结构域的保守变体。 本发明还涉及用于加速伤口愈合的组合物，其包含含有氨基酸序列的多肽或其具有血栓调节蛋白的EGF样结构域的保守变体。

公开(公告)号：US4774087A

公开(公告)日：1988-09-27

申请号：US83380

申请日：1987-08-14

Applicant: Hua-Lin Wu ,  Guey-Yueh Shi ,  Myron L. Bender

Inventor： Hua-Lin Wu ,  Guey-Yueh Shi ,  Myron L. Bender

IPC: A61K38/00 ,  C12N9/68 ,  A61K37/547 ,  A61K37/47

CPC classification number: C12N9/6435 ,  C12Y304/21007 ,  A61K38/00 ,  Y10S930/26

Abstract: Microplasmin and microplasminogen are plasmin and plasminogen derivatives produced by the action of plasmin non plasmin/plasminogen at high pH. The action of plasmin at this pH cleaves the heavy (A) chain of plasmin at the Arg.sub.529 - Lys.sub.503 or Lys.sub.530 -Leu.sub.531 bond and promotes disulfide bond rearrangement, producing microplasmin or microplasminogen consisting of a 30 or 31 residue C-terminal peptide derived from the A chain bound through new disulfide bonds to the intact B-chain of plasmin or plasminogen. The resulting products are significantly reduced in size and retain native activity.

Abstract translation: 微血浆和微量血浆原纤维蛋白溶酶原和纤维蛋白溶酶原衍生物在高pH下由纤溶酶非纤溶酶/纤溶酶原的作用产生。 纤溶酶在该pH下的作用在Arg529-Lys503或Lys530-Leu531键处切割重链（A）的纤溶酶链，并促进二硫键重排，产生由30或31个残基的C末端肽组成的微血浆或微血浆， 通过新的二硫键连接到纤溶酶或纤溶酶原的完整B链的链。 所得产品的尺寸显着减小并保留本地活动。

公开(公告)号：US11338019B2

公开(公告)日：2022-05-24

申请号：US16882508

申请日：2020-05-24

Applicant: Yi-Hsun Huang ,  Hua-Lin Wu

Inventor： Yi-Hsun Huang ,  Hua-Lin Wu

IPC: A61K38/36 ,  A61K38/18 ,  A61P27/02 ,  A61K38/17 ,  A61K9/00 ,  A61K9/06

Abstract: The present application relates to dual anti-angiogenic and anti-inflammatory effects of recombinant thrombomodulin domain 1 (TMD1). Specifically, an isolated recombinant polypeptide comprising an amino acid sequence that is at least 80% identical to TMD1 for use in treating an eye disease and/or an eye disorder associated with pathological ocular angiogenesis (POA) in a subject in need thereof is disclosed. The length of the recombinant polypeptide is no more than 200 amino acid residues. The eye disease and/or the eye disorder may be at least one selected from the group consisting of retinopathy of prematurity, diabetic retinopathy, and age-related macular degeneration. Use of TMD1 in the manufacture of a medicament for treating an eye disease and/or an eye disorder associated with vascular endothelial growth factor (VEGF)-induced ocular angiogenesis and/or hypoxia-inducible factor-1α (HIF-1α)-VEGF pathway is also disclosed.

公开(公告)号：US20170095537A1

公开(公告)日：2017-04-06

申请号：US14873880

申请日：2015-10-02

Applicant: Chih-Yuan MA ,  Guey-Yueh Shi ,  Hua-Lin Wu

Inventor： Chih-Yuan MA ,  Guey-Yueh Shi ,  Hua-Lin Wu

IPC: A61K38/36 ,  A61K9/00

CPC classification number: A61K38/366 ,  A61K9/0019

Abstract: A method for blocking, inhibiting and/or decreasing cluster of differentiation 14 (CD14) function, CD14-mediated cellular response and/or treating CD14-mediated pathological conditions is disclosed. The method comprises administering to a subject in need thereof a pharmaceutical composition comprising: (a) a therapeutically effective amount of a recombinant protein comprising an amino acid sequence that is at least 80% identical to SEQ ID NO: 1, wherein the recombinant protein does not comprises a lectin-like domain 1 of a human thrombomodulin; and (b) a pharmaceutically acceptable vehicle, carrier, diluent, excipients, and/or salt.

公开(公告)号：US08293710B2

公开(公告)日：2012-10-23

申请号：US11361560

申请日：2006-02-24

Applicant: Hua-Lin Wu ,  Guey-Yueh Shi

Inventor： Hua-Lin Wu ,  Guey-Yueh Shi

IPC: A61K38/18

CPC classification number: A61K48/00 ,  A61K38/366

Abstract: The invention relates to a method for treatment of wound healing, comprising administering to a patient in need of such treatment with an effective amount of a polypeptide comprising amino acid sequence or a conservative variant thereof having EGF-like domain of thrombomodulin. The invention also relates to a composition for the use of accelerating wound healing, comprising a polypeptide comprising amino acid sequence or a conservative variant thereof having EGF-like domain of thrombomodulin.

Abstract translation: 本发明涉及一种治疗伤口愈合的方法，其包括向需要这种治疗的患者施用有效量的包含氨基酸序列的多肽或其具有血栓调节蛋白EGF样结构域的保守变体。 本发明还涉及一种用于加速伤口愈合的组合物，其包含含有氨基酸序列的多肽或其具有血栓调节蛋白的EGF样结构域的保守变体。